GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (LTS:0EVI) » Definitions » Additional Paid-In Capital

Innate Pharma (LTS:0EVI) Additional Paid-In Capital : €390.98 Mil(As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Innate Pharma Additional Paid-In Capital?


Innate Pharma's quarterly additional paid-in capital increased from Dec. 2023 (€384.26 Mil) to Jun. 2024 (€386.05 Mil) and increased from Jun. 2024 (€386.05 Mil) to Dec. 2024 (€390.98 Mil).

Innate Pharma's annual additional paid-in capital increased from Dec. 2022 (€379.64 Mil) to Dec. 2023 (€384.26 Mil) and increased from Dec. 2023 (€384.26 Mil) to Dec. 2024 (€390.98 Mil).

Innate Pharma Additional Paid-In Capital Historical Data

The historical data trend for Innate Pharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Additional Paid-In Capital Chart

Innate Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 372.13 375.22 379.64 384.26 390.98

Innate Pharma Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 379.64 381.37 384.26 386.05 390.98

Innate Pharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Innate Pharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (LTS:0EVI) » Definitions » Additional Paid-In Capital
Comparable Companies
XPAR:GNFT XPAR:NANO XPAR:DBV XPAR:ALCLS XPAR:OSE XPAR:ALSEN XPAR:TNG XPAR:MAAT XPAR:ADOC XPAR:ALGAE VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
IPHYF:USA IPHA:USA IPH:France
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Website
https://www.innate-pharma.com
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Innate Pharma Headlines

No Headlines